| NEDD4 degrades TUSC2 to promote glioblastoma progression. | NEDD4 degrades TUSC2 to promote glioblastoma progression.
Rimkus TK, Arrigo AB, Zhu D, Carpenter RL, Sirkisoon S, Doheny D, Regua AT, Wong GL, Manore S, Wagner C, Lin HK, Jin G, Ruiz J, Chan M, Debinski W, Lo HW., Free PMC Article | 04/30/2022 |
| The TUSC2 Tumour Suppressor Inhibits the Malignant Phenotype of Human Thyroid Cancer Cells via SMAC/DIABLO Protein. | The TUSC2 Tumour Suppressor Inhibits the Malignant Phenotype of Human Thyroid Cancer Cells via SMAC/DIABLO Protein.
Mariniello RM, Orlandella FM, Stefano AE, Iervolino PLC, Smaldone G, Luciano N, Cervone N, Munciguerra F, Esposito S, Mirabelli P, Salvatore G., Free PMC Article | 11/21/2020 |
| MicroRNA-138 is a Prognostic Biomarker for Triple-Negative Breast Cancer and Promotes Tumorigenesis via TUSC2 repression. | MicroRNA-138 is a Prognostic Biomarker for Triple-Negative Breast Cancer and Promotes Tumorigenesis via TUSC2 repression.
Nama S, Muhuri M, Di Pascale F, Quah S, Aswad L, Fullwood M, Sampath P., Free PMC Article | 10/24/2020 |
| Low TUSC2 expression is associated with bladder cancer. | MicroRNA‑663b downregulation inhibits proliferation and induces apoptosis in bladder cancer cells by targeting TUSC2.
Chen J, Song B, Kong G. | 08/24/2019 |
| TUSC2P can suppresses the tumor function of esophageal squamous cell carcinoma by regulating TUSC2 expression and may also serve as a prognostic factor for esophageal squamous cell carcinoma patients. | TUSC2P suppresses the tumor function of esophageal squamous cell carcinoma by regulating TUSC2 expression and correlates with disease prognosis.
Liu F, Gong R, He B, Chen F, Hu Z., Free PMC Article | 11/10/2018 |
| these findings show that the combination of TUSC2-erlotinib induces additional novel vulnerabilities that can be targeted with Auranofin. | TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin.
Xiaobo C, Majidi M, Feng M, Shao R, Wang J, Zhao Y, Baladandayuthapani V, Song J, Fang B, Ji L, Mehran R, Roth JA., Free PMC Article | 04/28/2018 |
| Data show that TUSC2 is a direct target of miR-584, which is transcriptionally regulated by TWIST1. | TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.
Orlandella FM, Di Maro G, Ugolini C, Basolo F, Salvatore G., Free PMC Article | 03/3/2018 |
| FOXP1, TP53INP1, TNFAIP3, and TUSC2 were identified as miR-19a targets. | Uncovering Direct Targets of MiR-19a Involved in Lung Cancer Progression.
Yamamoto K, Ito S, Hanafusa H, Shimizu K, Ouchida M., Free PMC Article | 05/21/2016 |
| The therapeutic activity of TUSC2 could extend the use of erlotinib to lung cancer patients with wildtype EGFR. | Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
Dai B, Yan S, Lara-Guerra H, Kawashima H, Sakai R, Jayachandran G, Majidi M, Mehran R, Wang J, Bekele BN, Baladandayuthapani V, Yoo SY, Wang Y, Ying J, Meng F, Ji L, Roth JA., Free PMC Article | 03/5/2016 |
| TUSC2P and TUSC2 3'-UTR expression inhibits cell proliferation, survival, migration, invasion and colony formation, and increases tumor cell death. TUSC2P and TUSC2 3'-UTR bind to miRNAs and arrest their functions, leading to increased TUSC2 translation. | The pseudogene TUSC2P promotes TUSC2 function by binding multiple microRNAs.
Rutnam ZJ, Du WW, Yang W, Yang X, Yang BB., Free PMC Article | 10/31/2015 |
| The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner. | The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
Meng J, Majidi M, Fang B, Ji L, Bekele BN, Minna JD, Roth JA., Free PMC Article | 08/9/2014 |
| RNA sequence elements in FUS1 UTRs that regulate FUS1 protein express were identified. | Regulation of tumor suppressor gene FUS1 expression by the untranslated regions of mRNA in human lung cancer cells.
Lin J, Xu K, Gitanjali J, Roth JA, Ji L., Free PMC Article | 09/10/2011 |
| Absence of tumor suppressor FUS1 protein expression is associated with bone and soft tissue sarcomas. | Frequent absence of tumor suppressor FUS1 protein expression in human bone and soft tissue sarcomas.
Li G, Kawashima H, Ji L, Ogose A, Ariizumi T, Umezu H, Xu Y, Hotta T, Endo N. | 03/19/2011 |
| Data show that the recombinant FUS1 plasmid has been successfully cloned, which allows highly efficient FUS1 expression in E.coli strain Rosetta (DE3)2 plys. | [Recombinant prokaryotic plasmid construction and high expression of FUS1 gene].
Zhang B, Huo X, Peng L, Qi ZL, Xu XJ, Li Y, Qiu B, Zheng LK. | 08/23/2010 |
| The goal of this study was to analyze possible involvement of TUSC2 in malignant pleural mesothelioma. | Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects.
Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, Tsao A, Wistuba I, Roth J, Pass HI., Free PMC Article | 02/8/2010 |
| These results suggest that the three miRNAs are negative regulators of Fus1 expression in lung cancers. | miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1.
Du L, Schageman JJ, Subauste MC, Saber B, Hammond SM, Prudkin L, Wistuba II, Ji L, Roth JA, Minna JD, Pertsemlidis A., Free PMC Article | 01/21/2010 |
| FUS1 gene and Fus1 protein abnormalities could be used to develop new strategies for molecular cancer therapy for a significant subset of lung tumors. | Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer.
Prudkin L, Behrens C, Liu DD, Zhou X, Ozburn NC, Bekele BN, Minna JD, Moran C, Roth JA, Ji L, Wistuba II., Free PMC Article | 01/21/2010 |
| These results suggest that miR-378 enhances cell survival, tumor growth, and angiogenesis through repression of the expression of two tumor suppressors, Sufu and Fus-1. | MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression.
Lee DY, Deng Z, Wang CH, Yang BB., Free PMC Article | 01/21/2010 |
| Myristoylation is required for Fus1-mediated tumor-suppressing activity and suggest a novel mechanism for the inactivation of tumor suppressors in lung cancer. | Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells.
Uno F, Sasaki J, Nishizaki M, Carboni G, Xu K, Atkinson EN, Kondo M, Minna JD, Roth JA, Ji L. | 01/21/2010 |
| Overexpression of candidate tumor suppressor geneFUS1 isolated from the 3p21.3 homozygous deletionregion leads to G1 arrest and growth inhibition oflung cancer cells. | Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells.
Kondo M, Ji L, Kamibayashi C, Tomizawa Y, Randle D, Sekido Y, Yokota J, Kashuba V, Zabarovsky E, Kuzmin I, Lerman M, Roth J, Minna JD. | 06/25/2002 |